



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Tenofovir disoproxil fumarate
Catalog Number:	10198
Lot Number:	NG41-110-2
Release Category:	A
Provided:	20 mg
Chemical Name:	2, 4, 6, 8-Tetraoxa-5-phosphanonanedioic acid 5-[[(1R) -2-(6-amino-9H-purin-9-yl)-1-methylethoxy]-methyl]-bis (1-methylethyl) ester 5-oxide (2E)-2-butenedioate (1:1)
Empirical Formula:	$C_{19}H_{30}N_5O_{10}P \cdot C_4H_4O_4$
Molecular Weight:	635.5
CAS Num:	202138-50-9
Purity:	98.3% (by HPLC)
Solubility:	Soluble in water at 13.4mg/mL; Also soluble in methanol and moderately soluble in ethyl acetate and methylene chloride. Insoluble in hexanes.
Mechanical Action:	Tenofovir disoproxil fumarate is a prodrug of Tenofovir (catalog number 10199). Cellular enzymes convert tenofovir disoproxil fumarate to tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV reverse transcriptase by competing with the natural substrate, deoxyadenosine 5'-triphosphate, which after incorporation causes chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage: Room temperature. Once resuspended, working aliquots can be stored at -20°C .

Contributor: Division of AIDS, NIAID.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, NIAID, NIH: Tenofovir disoproxil fumarate."
This compound is restricted for "research purposes only" and is limited to 40 mg per requester per year. Not available for release to commercial organizations outside of the USA.
Recipient agrees that the reagent (Tenofovir disoproxil fumarate) use is permitted only as a standard for in vitro and/or studies in animals for inhibition of HIV replication.

Last Updated November 16, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.